Welcome to our dedicated page for Cytomx Therapeutics SEC filings (Ticker: CTMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CTMX SEC filings page on Stock Titan provides access to CytomX Therapeutics, Inc. regulatory documents as filed with the U.S. Securities and Exchange Commission. CytomX is a clinical-stage, oncology-focused biopharmaceutical company whose common stock trades on the Nasdaq Global Select Market under the symbol CTMX. Its filings offer detailed information on financial performance, risk factors, and the status of its development programs based on its PROBODY® therapeutic platform.
Investors can use this page to locate periodic reports and current reports on Form 8-K. For example, the company has filed 8-K reports to furnish quarterly financial results and to describe material events, such as updates on the CX-2051 Phase 1 study in colorectal cancer. These filings may discuss revenue from collaborations, research and development expenses, cash and investments, and other financial metrics, as well as narrative business updates.
The filings also provide context on clinical and safety disclosures. In one 8-K, CytomX reported an update on the CTMX-2051-101 Phase 1 study, including enrollment across multiple dose levels of CX-2051 and a treatment-related adverse event, along with the Safety Review Committee’s support for continued study execution. Such documents help readers understand how the company reports clinical progress and safety oversight in an official regulatory format.
Through Stock Titan, these SEC filings are complemented by AI-powered summaries that can help explain complex sections, highlight key points from lengthy reports, and surface items related to topics such as clinical trial status, collaboration revenues, or liquidity. Users interested in CytomX’s oncology pipeline, including varsetatug masetecan/CX-2051 and CX-801, can review the underlying filings alongside these AI-generated insights to form their own view of the company’s disclosures.
CytomX Therapeutics Inc schedule amendment shows The Vanguard Group reports 0 shares beneficially owned of Common Stock and 0% ownership as of 03/13/2026. The filing explains an internal realignment at The Vanguard Group that caused disaggregated reporting by subsidiaries.
CytomX Therapeutics Chief Medical Officer Yu‑Waye Chu reported an open-market sale of 21,279 shares of common stock at $6.423 per share. According to the filing, the shares were sold solely to cover tax and other government withholding obligations tied to vesting restricted stock units. After this transaction, Chu directly holds 189,446 shares, which includes 149,833 RSUs that may settle in stock as they vest.
CytomX Therapeutics CEO Sean A. McCarthy reported a tax-driven share sale. He sold 118,969 shares of common stock on March 17, 2026 at an average price of $6.423 per share, solely to satisfy tax and other government withholding obligations linked to vesting restricted stock units.
After this transaction, he directly holds 1,078,922 common shares, which include 457,500 RSUs, and indirectly holds 93,158 shares through the Sean A. McCarthy 2018 Trust, where he serves as trustee. The filing shows no remaining derivative securities such as stock options or warrants.
CytomX Therapeutics, Inc. executive Marcia Belvin, SVP and Chief Scientific Officer, reported an open-market sale of 31,492 shares of common stock on March 17, 2026 at $6.423 per share. The sale was made solely to satisfy tax or other government withholding obligations tied to vesting restricted stock units (RSUs).
After this transaction, Belvin directly holds 300,760 shares of common stock, which includes 135,833 RSUs. This filing reflects a compensation-related tax obligation rather than a discretionary portfolio trade.
CytomX Therapeutics, Inc. Chief Financial Officer Christopher Ogden sold 19,323 shares of common stock at an average price of $6.423 per share. The sale was made solely to satisfy tax and other government withholding obligations related to vesting restricted stock units. After this transaction, he directly holds 296,948 shares of common stock, which includes 173,082 restricted stock units.
CytomX Therapeutics completed an underwritten equity financing built around a large common stock and warrant sale. The company issued 45,990,567 shares of common stock at $5.30 per share and pre-funded warrants to purchase 1,179,245 shares at $5.29999 per warrant, with underwriters holding a 30-day option to buy up to 7,075,471 additional shares at the public price.
The transaction closed on March 19, 2026 and is expected to generate approximately $234.4 million in net proceeds after underwriting discounts and expenses. CytomX plans to use the cash to continue developing Varseta-M, advance other pipeline programs, and for general corporate and working capital purposes.
CytomX Therapeutics is offering 45,990,567 shares of common stock and pre-funded warrants to purchase 1,179,245 shares of common stock. The offering price per share is $5.30, producing estimated gross proceeds of $249,999,992 before underwriting discounts.
The prospectus supplement states net proceeds to the company are expected to be approximately $234.4 million (or about $269.6 million if the underwriters’ option is fully exercised), and that proceeds are intended to fund continued development of Varseta-M and other pipeline programs, and for general corporate purposes. Shares outstanding were 170,186,365 as of December 31, 2025.
CytomX Therapeutics is offering up to $250,000,000 of common stock and pre-funded warrants under a preliminary prospectus supplement dated March 16, 2026 ("Subject to Completion").
The prospectus discloses that our common stock trades on Nasdaq under the symbol CTMX and that the last reported sale price on March 13, 2026 was $4.68 per share. It states there were 170,186,365 shares outstanding as of December 31, 2025. The underwriters have a 30-day option to purchase up to $37,500,000 of additional shares. Proceeds are intended to fund continued development of Varseta-M, other pipeline programs, general corporate purposes and working capital.
CytomX Therapeutics, Inc. filed a shelf registration on Form S-3 to register securities for sale from time to time after the registration becomes effective. The prospectus covers common stock, preferred stock, debt securities, warrants and units. The prospectus notes the company’s Nasdaq listing under the symbol CTMX and a reported last sale price of $4.68 per share on March 13, 2026. The offering will be conducted by prospectus supplements that will specify amounts, prices, terms and use of proceeds.
CytomX Therapeutics reported 2025 results showing a sharp revenue decline alongside progress in its oncology pipeline. Revenue was $76.2 million for 2025, down from $138.1 million in 2024, mainly due to completion and slower recognition of collaboration revenues. Total operating expenses fell to $98.6 million from $113.1 million, but the company moved from net income of $31.9 million in 2024 to a net loss of $17.4 million in 2025, or $(0.15) per share.
CytomX ended 2025 with $137.1 million in cash, cash equivalents and investments, up from $100.6 million, and expects its cash runway to extend to the second quarter of 2027. Clinically, the company announced positive Phase 1 dose-expansion data for Varseta-M in advanced colorectal cancer and is targeting 2026 FDA interactions to align on a potential registrational trial. Combination studies of Varseta-M with bevacizumab and chemotherapy are underway or planned. The CX-801 interferon alpha-2b program in advanced melanoma is advancing through Phase 1, including a combination with KEYTRUDA, with initial combination data expected by the end of 2026.